Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of antihyperglycemic drugs that have demonstrated potent HbA1c reduction, low risk of hypoglycemia, with associated weight reduction, and proven cardiovascular and renal benefits.24 In this review we describe this type of drugs, their cardiovascular and renal benefits, as well as their clinical potential in patients with DKD, especially with the new oral semaglutide formulation, now available on the market
Gonzales, Jr., MSPAS, PA-C leads the clinical team
Comparison of Side Effects Combining these medications can lead to a compounded effect of these side effects, particularly increasing the risk of cardiovascular issues and intensifying gastrointestinal discomfort
Delays may occur due to customs clearance or carrier delays
Their function is dictated entirely by their unique three-dimensional structure